Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  MANAGEMENT DISCUSSION
Management Discussion      
Bandaram Pharma Packtech Ltd.
BSE Code 524602
ISIN Demat INE875N01036
Book Value 13.04
NSE Code NA
Dividend Yield % 0.34
Market Cap 521.37
P/E 0.00
EPS -0.31
Face Value 10  
Year End: March 2015
 

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Industry Structure & Development

The Indian Pharmaceutical Industry currently tops the charts amongst India’s science based industries with wide ranging capabilities in the complex field of drug manufacture & technology. With Leading MNC players from around the world accounting for potential takeover of Indian Companies and Indian Pharma Sector is growing very healthy along with economy. A highly organized sector, the Indian pharmaceutical industry is estimated to be worth $6billion, growing about 8 to 9% annually against the GDP projection of 6%. It ranks very high amongst all the third world countries. The pharma industry in India meets around 70% of the country’s demand for bulk drugs, drug intermediaries, pharma formulations, tablets, capusules, orals and injectibles. There are approximately 250 large units which form the core of the pharma industry in India.

About the Company

During the year ended the company has filed Capital Reduction petition with Honb'le High Court at Hyderabad and the petition is in final stage of hearing. Once the Carry Forward Losses are written off the management is confident of restarting operations of the company. Your company has started a new corporate office in Hyderabad and is in process of negotiating manufacturing some very vital Pharma Indigents that will have an assured buy back arrangement with couple of leading Pharmaceuticals manufacturers. Your company has already paid advance for identifying suitable land to put up a state of Art plant in coming near future. Management of company is working very hard to add to share holder's value.

Opportunities & Threats

Indian Pharma Sector is one of the sunrises Sector. With the new government initiative of MAKE in INDIA there is significant new opportunity in the Indian Pharma Industry. With many MNC's acquiring small and midsize Pharma companies. Your company foresees a better future in years to come.

The company is also trying to identify suitable land parcel where in company can start its further activities. Advances for the same have already been given and the process to negotiate and finalize should be completed once the Capital Reduction process is over.

Outlook

The management is trying to bring back company on the growth trajectory and revive its operations there by significantly adding to share holder's value.

By the order of the board

For Shiva Medicare Limited

Sd/- Amit Jain

(Director)

Place: Hyderabad

Date: 18.08.2015

Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.